Tuesday, April 24, 2007

DNDN Pick of the Day


DNDN Pick of the Day

kenttk, finally you are here

Before we begin with the stock to watch tonight, let evaluate our performance in the market. We have been repeating the same mistake, day in day out without analyzing our short coming and weaknesses for months if not years. Why are we ignoring the costly mistake that will siphon our reserves in the bank for our family and our future? I was also experiencing a similar dilemma back in year 1999. It is prudent for us think, plan, get one self organize and take action. We have to release ourselves form this uncomfortable situation, losing streak in the market.

We conducted brainstorming session in the work place with the employees to solve problem and get organized. Similarly, we also have to list down the details of our strengths and weaknesses to turn around from a “loser” to a “winner”. How can we achieve this?

We have to equip ourselves with (i) knowledge, (ii) trading tools, (iii) good machine, (iv) capital, and most crucial is to control our (v) emotion. If we do not have one of the four, it is the same like we are sitting on a chair with a three leg. Can we sit on the chair with three legs?

Let me share with you my experience when I was trading back in year 1999. I bought the stock based on finance yahoo message board recommendation, little knowledge in share market, without trading tools and my emotion outweighed the fundamentals and the results were disasters. Most of us are aware that 95% of traders and investors are losers. We must upgrade ourselves equipped of the above (i) to (v) and become one of the 5% winner camp. If we were to continue trading and missing one of the above 5, I am afraid we are going to lose money every month. May be we will win 2 or 3 out of 10 trades with little gains but lose big on another 7 trades. We have to invest, example subscribe to “real time chart” (is a must for a trader) that would help us to execute the buy and sell order, in order to be successful.

Emotion

We bring our emotion wherever we go, emotion relate to our personal character that will affect us in every decision that we make. We have to eliminate our negative emotion that is exist in our little voice to be independent and thus we are able see our blind spot and make a decision with a clear mind. Logically speaking, there are biases and prejudices in our little voice, we all have ones. “We have to remember negative emotion will outweigh fundamentals and logics.

My trading experience last night.

I was holding 4K shares of MGRM, and my target price to sell is $2.50. However, there was a negative comment of PFE made by Prudential and the high price for MGRM was $2.41, so, I sold my 4K shares with a small gains and the share prices of MGRM went down as low as 2.20 eventually. I do not allow my emotion to outweigh fundamentals, and I can buy back later at a lower price. The point here is that we must be realistic if we know that the target price is not within reach last night, we have to sell with a small gain.

Another case DNDN

I bought DNDN 300 shares at $16.70; the price went down to $16.39 after 15 minutes and was trading range from $16.40 to $16.60. After looking at fundamental, since yesterday was the first day reversal on the uptrend with huge volume, refer to attached chart, I did not sell in panic like most of traders in Wall Street did. The price closed $16.78 at the end of the day, after hour $17.05.

The above are the examples, how emotion can outweigh the fundamentals.

If we look at the chart of DNDN, the rally will usually last 3 to 4 days. But remember, DNDN is also another volatile trading pattern. I believe, there are many smart money, the Big Guys are watching and playing this stock. The result of DNDN products will be released by FDA on May 15.

I also bought 1K of MGRM.

ONT, have been accumulated by MM, range from 2.01 to 2.15, the support.
Next support 2.08 and 2.01.

ONSM, I don’t see any buying interest in the past 3 days.
Support 2.74 and 2.69, so I will buy again within this range.

Let’s practice what you have learned in order to be a successful person in everything you do.

8 comments:

Fakir said...

kenttk, morsid

MGRM

Two conflicting views from 2 analysts, one in favour and the other need PFE come up with something convincing

FDA Panel Reviews Pfizer HIV Drug

WASHINGTON (AP) -- A panel of government advisers meets Tuesday to review the safety and effectiveness of a Pfizer drug that, if approved, would become the first in a new class of treatments to fight the virus that causes AIDS.

Instead of attacking HIV directly like currently-approved drugs, Pfizer's maraviroc blocks the virus from entering white blood cells through a pathway present in some patients. Pfizer plans to offer the drug alongside a test developed by Monogram Biosciences Inc. that detects whether patients have the pathway.

"While more controversial than we had originally expected, we believe the favorable risk-benefit profile of maraviroc will lead to a panel recommendation for approval," writes Piper Jaffray analyst Thomas Weil in a research note published ahead of the meeting. FDA is not obligated to follow the recommendation of its panel, though it usually does. The agency is scheduled to make its final decision on maraviroc in June.
By Piper Jaffray


We think Pfizer is in a tough spot, as is well appreciated and reflected in its lowest-in-the-group price/earnings multiple. The company made a big bet on HDL-raising drug torcetrapib, which failed dramatically in November, and from here Pfizer needs to do something revolutionary to shore up its outlook and rekindle investor interest in the name, in our view.
Barron Finding Fault With Pfizer

Piper is talking about the PFE good product whilst Barron is talking about PFE earning
My view, Barron is waiting buy PFE at a discount after the downgrading

How about MGRM?
Smart money, institutional investors and traders are more concerned on maraviroc

I will hold my 1K share for the good news after trading hours, or may be after 12.00 midnight S’pore time

Fakir said...

Hmmm MGRM
luckily sold at 2.27 with coffee money
support at 2.11
So far DNDN

kenttk, morsid
are you around?

Morsid said...

not sure of market direction - seems like pharmaceuticals still the topic. VION lead the action.

Fakir said...

Biotech Bonanza
Majority active in R&D with new products and new testing devices to be approved by FDA. They are anticipating the demand from world population with aging and rich man sickness and the third world countries.

You should gone in DNDN, this morning low $17.10. Although look expensive, but you can 100 or 200 shares. Potential of making money is great than the stock below $5.00. This type of stock with good buying momentum is good for trader.

The support now is at $17.50

Fakir said...

Building of stair case is in progress at DNDN by by MMs

MGRM
accumulation is also in progress 2.14 and 2.15 whilst waiting for the release of PFE testing results. MGRM is still in play. Watch closely, the stock can go both way, up & down.
If result is good, get ready to join the band wagon as this one will be very furious.

Fakir said...

kenttk

never her anything from you
ONSM & ONT very quiet at this moment
I expect ONSM to move on Thursday or Friday for the next leg up. It would be good if we can buy below $2.80

Fakir said...

Stock that we have potential to make big money tomorrow

MGRM, either you 200% to 300% or lost 20% but you must be alert, probably you can't sleep tonight

Higher rewards lower risks

I am watching closely to push the button when the good news release later.

Fakir said...

either you win 200% to 300% or lose 20%. The downside of MGRM is limited but the upside is great